GlassScriptPhysician profile
Suzanne R Merkle
NPI 1184674798
$9,260.32
in general payments reported to CMS, 2019-2025
37 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,065 · 2020: $491 · 2021: $1,299 · 2022: $1,332 · 2023: $2,049 · 2024: $1,600 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,982 · Education: $91.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,981.51 |
| Education | $91.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,323.12 | 2019-2025 | |
| Janssen Biotech, INC. | $1,289.57 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $1,144.33 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Sun Pharmaceutical Industries INC. | $896.15 | 2019-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $575.28 | 2019-2025 | |
| Dermavant Sciences, INC. | $536.26 | 2023-2024 | Vtama |
| Genzyme Corporation | $456.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $455.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $373.91 | 2022-2024 | Sotyktu |
| Ucb, INC. | $288.29 | 2020-2025 | Cimzia, Bimzelx |
| Regeneron Healthcare Solutions, INC. | $240.78 | 2019-2024 | Dupixent |
| Leo Pharma INC. | $220.96 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $166.00 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $153.86 | 2023-2025 | Zoryve |
| Allergan, INC. | $141.65 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $115.03 | 2019-2024 | Seysara |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Lilly USA, LLC | $87.17 | 2022-2024 | Olumiant, Taltz, Ebglyss |
| Vyne Pharmaceuticals INC. | $80.72 | 2020-2021 | |
| Botanix Sb INC | $78.01 | 2025 | Sofdra |
| Amgen INC. | $74.16 | 2023-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.98 | 2023 | Spevigo |
| Fresenius Kabi USA, LLC | $58.69 | 2023 | Idacio |
| Biofrontera INC. | $48.15 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Lnhc, INC | $38.91 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.70 | 2021-2024 | Jublia, Duobrii |
| Prugen, INC. Pharmaceuticals | $26.68 | 2019-2020 | |
| Organon LLC | $26.66 | 2024-2025 | |
| Revance Therapeutics, INC. | $21.83 | 2024 | Daxxify |
| Kyowa Kirin, INC. | $21.41 | 2024 | Poteligeo |
| Smith+Nephew, INC. | $20.91 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $18.67 | 2022 | |
| Epi Health, LLC | $18.49 | 2022 | |
| Journey Medical Corporation | $16.12 | 2025 | |
| Nabriva Therapeutics, Plc | $15.35 | 2021 | |
| Verrica Pharmaceuticals INC. | $14.74 | 2023 | Ycanth |
| Strata Skin Sciences, INC. | $13.80 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Merkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.